Novo Nordisk adds another obesity biotech in potential $500 deal
The transaction, worth about $16 million upfront and up to $500 million in upcoming milestones, builds upon Novo Nordisk’s collaboration with Embark Laboratories from 2018.
Source: mmm-online.com